APTX Aptinyx Inc

100
Price
$0.096
Increased by +3.11%
Dollar Volume (20D)
20.15 K
ADR%
60.13
Earnings Report Date (estimate)
Mar 28, 24
Shares Float
58.78 M
Shares Outstanding
67.72 M
Shares Short
2.23 M
Market Cap.
6.5 M
Beta
1.22
Price / Earnings
N/A
20D Range
0.01 0.1
50D Range
0.01 0.1
200D Range
0.01 0.19
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 15, 23 0
Increased by +100%
-0.05
Increased by +100%
Aug 4, 23 0
Increased by +100%
-0.05
Increased by +100%
May 18, 23 -0.18
Increased by +37.93%
-0.14
Decreased by -28.57%
Mar 30, 23 -0.18
Increased by +37.93%
-0.19
Increased by +5.26%
Nov 8, 22 -0.23
Increased by +25.81%
-0.24
Increased by +4.17%
Aug 4, 22 -0.26
Increased by +10.34%
-0.28
Increased by +7.14%
May 12, 22 -0.29
Decreased by -31.82%
-0.3
Increased by +3.33%
Mar 23, 22 -0.29
Decreased by -45%
-0.35
Increased by +17.14%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0
Decreased by N/A%
-21.81 M
Decreased by -7.57%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
25.97 M
Increased by +232.43%
Increased by +N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by -100%
-15.1 M
Increased by +28.9%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by -100%
-18.23 M
Increased by +8.02%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by -100%
-20.27 M
Decreased by -42.52%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-19.61 M
Decreased by -70.7%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 4.93 K
Decreased by -98.08%
-21.23 M
Decreased by -87.26%
Decreased by -430.82 K%
Decreased by -9.67 K%
Jun 30, 21 5.07 M
Increased by +934.69%
-19.82 M
Decreased by -58.34%
Decreased by -390.91%
Increased by +84.7%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.